Amlodipine Besylate With ValsartanAmlodipine/Valsartan Novartis
Recommended CardiovascularRestrictedNot applicable line
Hypertension in patients who are not adequately controlled with either amlodipine or valsartan monotherapy
1
Submissions
2008–08
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Jul 2010 Recommended Antihypertensive
- Meeting Jul 2008 Recommended Blood pressure
Access path
- TGA registered · Amlodipine/Valsartan Novartis
TGA label narrower than the PBS population
- Jul 2008Recommended · restricted
vs amlodipine and valsartan at equivalent doses
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis performed; no ICER calculated by design
The PBAC recommended listing of amlodipine with valsartan in accordance with the combination guidelines, on a cost-minimisation basis compared with its constituent components, amlodipine and valsartan at equivalent doses. PBAC · 2008
Cost-effectiveness accepted
Decision context
Populationpatients who are not adequately controlled with either amlodipine or valsartan monotherapy
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2008 | Recommended · restricted | amlodipine and valsartan at equivalent doses | — | RCT · null |
Similar precedents
Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide93%Olmesartan Medoxomil With Amlodipine80%Perindopril Arginine With Amlodipine Besylate79%Telmisartan With Amlodipine79%Valsartan With Hydrochlorothiazide79%Ramipril With Felodipine77%Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide74%Olmesartan Medoxomil With Hydrochlorothiazide74%
Regulatory · TGA
Label narrower than PBS population — PBAC restricted subsidy to patients inadequately controlled on amlodipine or valsartan monotherapy, a subset of all hypertension patients.